{"entity":{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","aka":[],"tldr":"Shanghai Juncell Therapeutics is a China-based cell therapy company running 2 late-stage cancer trials of GC101 TIL in melanoma and non-small-cell lung cancer.","summary":"Shanghai Juncell Therapeutics, based in Shanghai, China, is a cell therapy company. Juncell Therapeutics is a biotech enterprise focused on research, development and commercialisation of innovative cell therapies for solid tumours, using tumour-infiltrating lymphocyte (TIL) technology platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing GC101 TIL in melanoma and non-small-cell lung cancer. The largest, NCT06703398 (A Study of GC101 TIL in Advanced Melanoma), plans to enrol 98 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.juncell.com/"},{"label":"ClinicalTrials.gov: trials led by Shanghai Juncell Therapeutics","url":"https://clinicaltrials.gov/search?lead=Shanghai%20Juncell%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["gc101-til"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06703398","nct07560111"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"cell-therapy","website":"https://www.juncell.com/","founded":2019,"stage":"growth","investors":[],"funding":[]},"route":"/companies/shanghai-juncell-therapeutics/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"gc101-til","kind":"drug","name":"GC101 TIL","route":"/drugs/gc101-til/"}],"trial":[{"id":"nct07560111","kind":"trial","name":"A Phase II Study of GC101 in NSCLC","route":"/trials/nct07560111/"},{"id":"nct06703398","kind":"trial","name":"A Study of GC101 TIL in Advanced Melanoma","route":"/trials/nct06703398/"}]}}